However, B cell depletion with the humanized anti-CD20 monoclonal antibody (72) ocrelizumab, which is approved for PPMS, does not deliver significant neuroprotective effects as assessed by serial blood measurements of neurofilament light chain (NfL) (73). Here, NEFL is linked to primary progressive multiple sclerosis.